K-Cath Device For Filtering Undesired Compounds From The Blood
Percutaneous Coronary Interventions (PCI) is considered one of the most important procedures in modern medicine. In this procedure Iodine based contrast material (CM) is injected in the arteries to visualize the blood vessels under Fluoroscopy. Unfortunately, CM may induce Acute Kidney Injury, mainly through direct toxicity and damage to its blood supply.
One out of three patients undergoing PCI have Chronic Kidney Disease (CKD), which increases the immediate risk to suffer from CI-AKI for up to 30%.
Current preventive measures are limited and none of those eliminate CM:
– Not applicable in emergencies
– Risk of fluid overload and pulmonary edema
– Require long Pre-Op prep time
– Limits operation
– Require two step procedures
– Limited use in emergencies
K-Cath – Intravascular multi-channel catheter, with a microporous semi-permeable wall.
Utilizing negative pressure gradient, osmotic and vascular pressure to eliminate CM and small molecules from the blood stream. Without the removal of large molecules and cells.
– Real time contrast media elimination
– Real time volume replacement and dilution
– No change to the operator’s modus-operandi
– Applicable for all angiography procedures
- Percutaneous Coronary Interventions (PCI) with risk of Contrast Induced Acute Kidney Injury (CI-AKI)
- Other angiographic procedures:
– Interventional cardiology (valve replacement, valvuloplasty, closure of cardiac malformations)
U.S. Provisional – US 63/299,088
TAM (Totally Available Market) is $500M.
There are 1 M PCI procedures performed annually in the U.S.
>300K patients according to the statistics are suffering from CKD and are at risk to develop CI-AKI.